NEKTAR THERAPEUTICS Logo

NEKTAR THERAPEUTICS

Biopharma firm developing medicines for autoimmune and inflammatory conditions.

NKTR | US

Overview

Corporate Details

ISIN(s):
US6402681083
LEI:
Country:
United States of America
Address:
455 MISSION BAY BOULEVARD SOUTH, 94158 SAN FRANCISCO

Description

Nektar Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel medicines for autoimmune and inflammatory conditions. The company's research centers on modulating the immune system to resolve imbalances and restore homeostasis. By leveraging its expertise in immune pathways, Nektar aims to develop first-in-class, disease-modifying therapies that address the root causes of immune dysfunction. Its pipeline includes investigational candidates such as rezpegaldesleukin, a therapy designed to stimulate regulatory T cells for the treatment of conditions like severe alopecia areata.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-26 02:30
4
English 8.5 KB
2025-11-26 02:29
4
English 8.6 KB
2025-11-26 02:28
4
English 8.5 KB
2025-11-25 21:35 English 7.4 KB
2025-11-25 21:32 English 7.1 KB
2025-11-25 21:28 English 7.3 KB
2025-11-21 22:06
CURRENT REPORT
English 65.2 KB
2025-11-14 22:31 English 9.3 KB
2025-11-14 22:23 English 9.5 KB
2025-11-13 23:45 English 11.0 KB
2025-11-12 22:17
REGISTRATION STATEMENT
English 143.7 KB
2025-11-12 22:09
424B5
English 162.4 KB
2025-11-12 22:06
S-3ASR
English 352.5 KB
2025-11-10 12:31
CURRENT REPORT
English 107.0 KB
2025-11-06 23:58
10-Q
English 1.8 MB

Automate Your Workflow. Get a real-time feed of all NEKTAR THERAPEUTICS filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for NEKTAR THERAPEUTICS

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for NEKTAR THERAPEUTICS via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Access Bio, Inc. Logo
Develops and manufactures in vitro diagnostic solutions for infectious diseases.
United States of America
950130
ACHIEVE LIFE SCIENCES, INC. Logo
A late-stage pharmaceutical company developing a treatment for nicotine dependence.
United States of America
ACHV
AC Immune SA Logo
Biopharmaceutical firm developing precision medicine for neurodegenerative diseases.
United States of America
ACIU
Aclaris Therapeutics, Inc. Logo
Clinical-stage biopharmaceutical company developing drugs for immuno-inflammatory diseases.
United States of America
ACRS
Acrivon Therapeutics, Inc. Logo
Clinical-stage biopharma using proteomics to develop precision oncology therapies.
United States of America
ACRV
Acticor Biotech Logo
Develops treatments for thrombotic diseases, focusing on acute ischemic stroke.
France
ALACT
Actinium Pharmaceuticals, Inc. Logo
Clinical-stage company developing targeted radiotherapies for difficult-to-treat cancers.
United States of America
ATNM
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing therapies for cancers with high unmet needs.
United States of America
ACTU
AcuCort AB Logo
Develops user-friendly drug formulations for severe and acute allergic reactions.
Sweden
ACUC
Acumen Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing targeted therapies for Alzheimer's disease.
United States of America
ABOS

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.